SCHEMBL17737538

SCHEMBL17737538

C[C@@H](C(=O)Nc1ccc(Cl)cc1)C1CCC(c2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 6/20 0.58
▸ TDO2 P48775 3/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ CYP3A4 P08684 2/20 0.53
▸ CYP2C8 P10632 1/20 0.53
▸ KCNH2 Q12809 1/20 0.53
▸ NPC1 O15118 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51
▸ RELA Q04206 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CCR1 P32246 1/20 0.48
▸ KLK7 P49862 1/20 0.47
▸ PRCP P42785 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20838737 1.00 IDO1 (0.58) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL17737066 1.00 IDO1 (0.58) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL20838754 0.90 IDO1 (0.50) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL17737122 0.87 IDO1 (0.51) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL20838723 0.87 IDO1 (0.51) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL17737121 0.87 IDO1 (0.51) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL20852663 0.87 IDO1 (0.51) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL20852664 0.85 KLK7 (0.55) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL20838715 0.85 KLK7 (0.55) IDO1TDO2CYP2C9CYP3A4CYP2C8
SCHEMBL17737525 0.85 KLK7 (0.55) IDO1TDO2CYP2C9CYP3A4CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11242319-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2022-02-08 — — US disclosed
US-20190092729-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2019-03-28 — — US disclosed
WO-2016073738-A2 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. (US) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242319-B2 Immunoregulatory agents IDO1, IDO2, INMT IDO1 1/4885TDO2 5/4885CYP2C9 2655/4885
US-20190092729-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT IDO1 1/4885TDO2 5/4885CYP2C9 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback